KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Tax Provisions: 2011-2025

Historic Tax Provisions for Vertex Pharmaceuticals (VRTX) over the last 14 years, with Sep 2025 value amounting to $215.9 million.

  • Vertex Pharmaceuticals' Tax Provisions rose 20.82% to $215.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $773.6 million, marking a year-over-year increase of 4.63%. This contributed to the annual value of $784.1 million for FY2024, which is 3.14% up from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Tax Provisions is $215.9 million, which was down 13.67% from $250.1 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Tax Provisions ranged from a high of $257.9 million in Q4 2022 and a low of -$111.2 million during Q2 2021.
  • Moreover, its 3-year median value for Tax Provisions was $191.7 million (2023), whereas its average is $190.4 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Tax Provisions tumbled by 789.60% in 2021 and then skyrocketed by 292.36% in 2022.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Tax Provisions stood at $100.8 million in 2021, then soared by 155.85% to $257.9 million in 2022, then slumped by 30.67% to $178.8 million in 2023, then climbed by 25.00% to $223.5 million in 2024, then increased by 20.82% to $215.9 million in 2025.
  • Its last three reported values are $215.9 million in Q3 2025, $250.1 million for Q2 2025, and $84.1 million during Q1 2025.